Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gavin R. Norton"'
Publikováno v:
Journal of cardiovascular pharmacology. 79(3)
Myocardial metabolic abnormalities are well-recognized alterations in chronic heart failure, effects that may contribute to progressive cardiac dysfunction. However, whether metabolic alterations in-part mediate their deleterious effects by modifying
Autor:
Frédéric Michel, Aletta M.E. Millen, Gavin R. Norton, Lebogang Mokotedi, Angela J. Woodiwiss
Publikováno v:
Journal of Cardiovascular Pharmacology. 71:340-346
Sodium (Na) intake increases vascular reactivity. Whether low potassium (K) intake affects vascular reactivity-associated blood pressure (BP) changes is uncertain. This study aimed to determine whether Na-induced increases in BP and vascular reactivi
Autor:
Frédéric Michel, Gavin R. Norton, Mhlengi M. Magubane, Angela J. Woodiwiss, Kennedy H. Erlwanger
Publikováno v:
Journal of cardiovascular pharmacology. 70(3)
Chronic β-adrenergic stimulation induces left ventricular (LV) remodeling in male but not in female spontaneously hypertensive rats (SHRs). However, the role of sex steroids in mediating these effects has not been determined. The aim of the present
Autor:
Danelle Badenhorst, Angela J. Woodiwiss, Richard Brooksbank, Gavin R. Norton, Hans Strijdom, Raul J Correia, Demetri G. A. Veliotes
Publikováno v:
Journal of Cardiovascular Pharmacology. 56:203-211
Although in hypertension beta-adrenoreceptor activation promotes the transition from cardiac hypertrophy to pump dysfunction, the use of beta-blockers is controversial. As adrenergic activation may mediate adverse effects on the heart through the ren
Publikováno v:
Journal of Cardiovascular Pharmacology. 47:221-227
Although increases in myocardial synaptic norepinephrine concentrations contribute toward the progression to heart failure in hypertension, the stimuli for norepinephrine release are unclear. In this study we explored whether neurotensin, a neuropept
Publikováno v:
Journal of cardiovascular pharmacology. 63(6)
A reduced testosterone concentration characterizes heart failure and independently predicts outcomes. Although testosterone replacement therapy may have non cardiac-related therapeutic benefits in heart failure, whether reduced testosterone concentra